Jane Street’s Atara Biotherapeutics ATRA Stock Holding History

Jane Street’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-624	Closed	-$122K	–	9662
2022 Q2	$122K	Sell	624 -172	-22%	-$28.1K	﹤0.01%	8527
2022 Q1	$185K	Sell	796 -36	-4%	-$11.5K	﹤0.01%	9085
2021 Q4	$328K	Buy	832 +424	+104%	+$178K	﹤0.01%	8005
2021 Q3	$183K	Buy	+408	New	+$146K	﹤0.01%	8919
2021 Q1	–	Sell	-580	Closed	-$285K	–	9062
2020 Q4	$285K	Buy	+580	New	+$268K	﹤0.01%	6486
2018 Q2	–	Sell	-704	Closed	-$686K	–	4947
2018 Q1	$686K	Buy	+704	New	+$642K	﹤0.01%	3115

Other funds holding ATRA

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SCA

STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.57B AUM 26.96% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Jane Street's ATRA Position: Q2 2026 in Review

Jane Street reduced its Atara Biotherapeutics (ATRA) stake by 10% in Q2 2026, selling an estimated $28.1K and leaving 30,345 shares worth $348K. The position accounts for ﹤0.01% of the portfolio, ranked #8876.

Jane Street first reported a position in ATRA in Q3 2015 and has held it in 22 quarters since. The position peaked at $1.4M in Q3 2020. 36 funds tracked by Wall St. Rank hold ATRA as of Q2 2026.

Jane Street held 30,345 shares of Atara Biotherapeutics worth $348K as of Q2 2026.
Jane Street sold 3,525 Atara Biotherapeutics shares in Q2 2026, an estimated $28.1K.
Atara Biotherapeutics made up ﹤0.01% of Jane Street's portfolio in Q2 2026, its #8876 holding.
Jane Street first reported a position in Atara Biotherapeutics in Q3 2015 and has held it in 22 quarters since.
Jane Street's Atara Biotherapeutics position peaked at $1.4M in Q3 2020.
36 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.